New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2013
08:04 EDTNAVBNavidea completes study of radiopharmaceutical NAV4694
Navidea Biopharmaceuticals announced the completion of a study of its novel radiopharmaceutical NAV4694 as a biomarker for visual detection and quantification of cerebral b-amyloid in diagnosing Alzheimer's disease, or AD. The study was designed and conducted by Navidea's partner, AstraZeneca, to assess the effects of various mass amounts of AZD4694, or NAV4694, on safety and the efficacy of Positron Emission Tomography scanning in subjects with AD and in healthy volunteers. Evaluations were completed on the effects of two mass doses of the radioligand on binding parameters and overall image quality. These endpoints are typical and important requirements of drug registration dossiers filed with regulatory authorities for approval of diagnostic agents.
News For NAVB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
07:34 EDTNAVBNavidea reiterates FY15 Lymphoseek product revenue view $10M-$12M
Subscribe for More Information
07:34 EDTNAVBNavidea reports Q2 EPS (6c), two estimates (4c)
Subscribe for More Information
July 29, 2015
07:32 EDTNAVBNavidea wins $1.7M fast track NIH SBIR grant for evaluation of RA treatment
Subscribe for More Information
July 28, 2015
07:35 EDTNAVBNavidea, MGH to evaluate Manocept for detection of cardiovascular disease
Subscribe for More Information
July 23, 2015
08:50 EDTNAVBNavidea announces peer-reviewed publication of data on Lymphoseek
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use